BR112015010283A8 - bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina - Google Patents
bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacinaInfo
- Publication number
- BR112015010283A8 BR112015010283A8 BR112015010283A BR112015010283A BR112015010283A8 BR 112015010283 A8 BR112015010283 A8 BR 112015010283A8 BR 112015010283 A BR112015010283 A BR 112015010283A BR 112015010283 A BR112015010283 A BR 112015010283A BR 112015010283 A8 BR112015010283 A8 BR 112015010283A8
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- producing
- recombinant glycoprotein
- modified
- methods
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 4
- 108090000288 Glycoproteins Proteins 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000894006 Bacteria Species 0.000 title abstract 2
- 150000004676 glycans Chemical class 0.000 title abstract 2
- 229920001282 polysaccharide Polymers 0.000 title abstract 2
- 239000005017 polysaccharide Substances 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000001236 prokaryotic cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723408P | 2012-11-07 | 2012-11-07 | |
| PCT/EP2013/073266 WO2014072405A1 (en) | 2012-11-07 | 2013-11-07 | Production of recombinant vaccine in e. coli by enzymatic conjugation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015010283A2 BR112015010283A2 (pt) | 2017-07-11 |
| BR112015010283A8 true BR112015010283A8 (pt) | 2021-07-06 |
Family
ID=49552366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015010283A BR112015010283A8 (pt) | 2012-11-07 | 2013-11-07 | bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20150273043A1 (enExample) |
| EP (3) | EP3444352B1 (enExample) |
| JP (2) | JP6412875B2 (enExample) |
| KR (1) | KR20150079964A (enExample) |
| CN (1) | CN105008539B (enExample) |
| AU (2) | AU2013343520B2 (enExample) |
| BR (1) | BR112015010283A8 (enExample) |
| CA (2) | CA2889767C (enExample) |
| EA (1) | EA201590705A1 (enExample) |
| ES (3) | ES2713166T3 (enExample) |
| IL (1) | IL238586A0 (enExample) |
| MX (1) | MX366912B (enExample) |
| SG (1) | SG11201503308XA (enExample) |
| TR (1) | TR201903066T4 (enExample) |
| WO (1) | WO2014072405A1 (enExample) |
| ZA (1) | ZA201503097B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010322454B2 (en) * | 2009-11-19 | 2016-05-19 | Glaxosmithkline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| US11220676B2 (en) * | 2013-10-11 | 2022-01-11 | Glaxosmithkline Biological Sa | Methods of host cell modification |
| EA035991B9 (ru) | 2014-02-24 | 2020-10-21 | Глаксосмитклайн Байолоджикалс С.А. | Новый полисахарид и его применения |
| SI3131577T1 (sl) * | 2014-04-17 | 2020-08-31 | Glaxosmithkline Biologicals S.A. | Modificirane gostiljske celice in uporabe le-teh |
| SG11201700325SA (en) * | 2014-08-08 | 2017-02-27 | Glycovaxyn Ag | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
| AU2016224006B8 (en) * | 2015-02-26 | 2020-03-19 | Vaxnewmo Llc | Acinetobacter O-oligosaccharyltransferases and uses thereof |
| GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| CN105963691B (zh) * | 2016-07-03 | 2020-05-01 | 查文娟 | 一种肺炎链球菌疫苗 |
| CN106929573B (zh) * | 2017-02-21 | 2020-06-09 | 南开大学 | 对嗜肺军团菌O12型的wzm和wecA基因特异的核苷酸序列及其应用 |
| GB201712678D0 (en) * | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| WO2019043245A1 (en) * | 2017-09-04 | 2019-03-07 | London School Of Hygiene And Tropical Medicine | MICROBIAL CELLS EXPRESSING STREPTOCOCCAL SERROTYPES |
| WO2019090138A2 (en) * | 2017-11-04 | 2019-05-09 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Immunogenic conjugates and methods of use thereof |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| WO2019241672A2 (en) | 2018-06-16 | 2019-12-19 | Vaxnewmo Llc | Glycosylated comp pilin variants, methods of making and uses thereof |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| EP3650044A1 (en) * | 2018-11-06 | 2020-05-13 | ETH Zürich | Anti-glycan vaccines |
| US12350342B2 (en) | 2018-12-21 | 2025-07-08 | Vaxnewmo Llc | O-linked glycosylation recognition motifs |
| IL286467B1 (en) | 2019-03-18 | 2025-10-01 | Janssen Pharmaceuticals Inc | Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| CN112369722B (zh) * | 2020-05-08 | 2023-03-17 | 湖北中烟工业有限责任公司 | 加热不燃烧装置和温度控制方法 |
| CN111518738B (zh) * | 2020-05-08 | 2022-02-08 | 徐州海润生物科技有限公司 | 重组卡介苗及其制备方法和应用 |
| CA3185719A1 (en) * | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
| US20230293657A1 (en) | 2020-06-25 | 2023-09-21 | Glaxosmithkline Biologicals Sa | Vaccine |
| KR20230043157A (ko) | 2020-09-17 | 2023-03-30 | 얀센 파마슈티칼즈, 인코포레이티드 | 다가 백신 조성물 및 이의 용도 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| EP4452308A1 (en) | 2021-12-22 | 2024-10-30 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| GB202302579D0 (en) | 2023-02-23 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2025172892A1 (en) | 2024-02-16 | 2025-08-21 | Glaxosmithkline Biologicals Sa | Modified proteins and methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2638595A (en) * | 1994-05-16 | 1995-12-05 | Uab Research Foundation, The | (streptococcus pneumoniae) capsular polysaccharide genes and flanking regions |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US7541043B2 (en) | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| CA2477794C (en) | 2002-03-07 | 2013-08-20 | Eidgenoessische Technische Hochschule Zuerich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| JP5356807B2 (ja) | 2005-05-11 | 2013-12-04 | アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ | 原核細胞由来の組み換えｎ−グリコシル化タンパク質 |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| CA2756170C (en) * | 2009-03-23 | 2019-04-02 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
| KR20120085240A (ko) | 2009-07-17 | 2012-07-31 | 오션 하베스트 테크놀로지 (캐나다) 아이엔씨. | 어류 사료에서 합성 첨가제를 대체하는 천연 및 지속 가능 해조류 배합 |
| ES2844596T3 (es) | 2010-05-06 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Vacunas de bioconjugados de bacterias grampositivas capsulares |
| TR201904022T4 (tr) * | 2012-10-12 | 2019-04-22 | Glaxosmithkline Biologicals Sa | Konakçı hücre modifikasyon yöntemleri. |
-
2013
- 2013-11-07 SG SG11201503308XA patent/SG11201503308XA/en unknown
- 2013-11-07 CA CA2889767A patent/CA2889767C/en active Active
- 2013-11-07 CN CN201380069524.XA patent/CN105008539B/zh not_active Expired - Fee Related
- 2013-11-07 WO PCT/EP2013/073266 patent/WO2014072405A1/en not_active Ceased
- 2013-11-07 ES ES13788753T patent/ES2713166T3/es active Active
- 2013-11-07 KR KR1020157014830A patent/KR20150079964A/ko not_active Withdrawn
- 2013-11-07 EP EP18198665.4A patent/EP3444352B1/en active Active
- 2013-11-07 ES ES18198665T patent/ES2848774T3/es active Active
- 2013-11-07 EP EP18211761.4A patent/EP3508579B1/en active Active
- 2013-11-07 CA CA3125293A patent/CA3125293A1/en active Pending
- 2013-11-07 EA EA201590705A patent/EA201590705A1/ru unknown
- 2013-11-07 BR BR112015010283A patent/BR112015010283A8/pt not_active Application Discontinuation
- 2013-11-07 EP EP13788753.5A patent/EP2917351B1/en active Active
- 2013-11-07 MX MX2015005797A patent/MX366912B/es active IP Right Grant
- 2013-11-07 AU AU2013343520A patent/AU2013343520B2/en not_active Ceased
- 2013-11-07 ES ES18211761T patent/ES2882282T3/es active Active
- 2013-11-07 TR TR2019/03066T patent/TR201903066T4/tr unknown
- 2013-11-07 JP JP2015541130A patent/JP6412875B2/ja not_active Expired - Fee Related
- 2013-11-07 US US14/440,311 patent/US20150273043A1/en not_active Abandoned
-
2015
- 2015-05-03 IL IL238586A patent/IL238586A0/en unknown
- 2015-05-06 ZA ZA2015/03097A patent/ZA201503097B/en unknown
-
2017
- 2017-12-20 AU AU2017279688A patent/AU2017279688B2/en not_active Ceased
-
2018
- 2018-07-13 US US16/034,906 patent/US10973901B2/en not_active Expired - Fee Related
- 2018-10-01 JP JP2018186302A patent/JP6833785B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015010283A8 (pt) | bactéria gram-negativa modificada para a produção de um polissacarídeo, glicoproteína recombinante, métodos de produzir uma glicoproteína recombinante e de produzir uma vacina de gliconjugado, célula de e. coli modificada, e, vacina | |
| MX2020000969A (es) | Sialil-transferasas y su uso en la produccion de oligosacaridos sialilados. | |
| BR112015011933A2 (pt) | composições bacterianas sinérgicas e métodos de produção e uso das mesmas | |
| MX380438B (es) | Nuevo polisacárido y usos del mismo. | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| ZA201601534B (en) | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses | |
| MX381456B (es) | Regulador de ph de transduccion. | |
| EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| SG10201900948PA (en) | Modified nucleotide linkers | |
| BR112013027307A2 (pt) | método para tratar uma matriz de tecido; matriz de tecido acelular | |
| BR112015006426A2 (pt) | composições nutricionais que incluem beta-hidróxi-beta-metilbutirato de cálcio, proteína e baixos níveis de eletrólitos | |
| BR112014008700A2 (pt) | composições úteis no tratamento de nefropatia e processos para preparação das mesmas | |
| BR112015021993A2 (pt) | composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| PL3321355T3 (pl) | Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne | |
| BR112016016539A2 (pt) | micro-organismos recombinantes enriquecidos com carboidratos | |
| BR112017001550A2 (pt) | enxerto de tecido | |
| IN2014DN00161A (enExample) | ||
| MX363187B (es) | Métodos y composiciones para impedir la incorrecta incorporación de norleucina en proteínas. | |
| MY180645A (en) | Microbial production of fatty amines | |
| IN2014CN03884A (enExample) | ||
| MX355719B (es) | Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano. | |
| MX2014010958A (es) | Composicion de celulas inmunoestimuladora activada y sus usos. | |
| EA201590782A1 (ru) | Оксирановые амины | |
| MX2014007760A (es) | Bacterias con unidades transcripcionales reconstruidas y los usos de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS SA (BE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |